TY - JOUR
T1 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8
AU - Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Konuma, Takaaki
AU - Miyazaki, Yasushi
AU - Uchida, Naoyuki
AU - Ohashi, Kazuteru
AU - Kondo, Tadakazu
AU - Nakamae, Hirohisa
AU - Takahashi, Satoshi
AU - Mori, Takehiko
AU - Ozawa, Yukiyasu
AU - Kato, Chiaki
AU - Iwato, Koji
AU - Fukuda, Takahiro
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Ishiyama, Ken
N1 - Funding Information:
Financial disclosure: This work was supported in part by a Research Grant for Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare, Japan.
Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Trisomy 8 (+8) is 1 of the most common cytogenetic abnormalities in adult patients with myelodysplastic syndrome (MDS). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with MDS harboring +8 remains unclear. To evaluate the outcome and prognostic factors in patients with MDS harboring +8 as the sole cytogenetic abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 381 adult patients with MDS harboring +8 treated with allogeneic HSCT between 1990 and 2013. With a median follow-up period of 53 months, the probability of overall survival and cumulative incidence of relapse at 4 years were 51% and 22%, respectively. In the multivariate analysis, age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. Nevertheless, no significant impact of the outcome was observed in patients with 1 cytogenetic abnormality in addition to +8. Although 221 patients (58%) had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.
AB - Trisomy 8 (+8) is 1 of the most common cytogenetic abnormalities in adult patients with myelodysplastic syndrome (MDS). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with MDS harboring +8 remains unclear. To evaluate the outcome and prognostic factors in patients with MDS harboring +8 as the sole cytogenetic abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 381 adult patients with MDS harboring +8 treated with allogeneic HSCT between 1990 and 2013. With a median follow-up period of 53 months, the probability of overall survival and cumulative incidence of relapse at 4 years were 51% and 22%, respectively. In the multivariate analysis, age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. Nevertheless, no significant impact of the outcome was observed in patients with 1 cytogenetic abnormality in addition to +8. Although 221 patients (58%) had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.
KW - Additional abnormality
KW - Allogeneic hematopoietic stem cell transplantation
KW - Cytogenetics
KW - Myelodysplastic syndrome
KW - Trisomy 8
UR - http://www.scopus.com/inward/record.url?scp=85006459142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006459142&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2016.10.015
DO - 10.1016/j.bbmt.2016.10.015
M3 - Article
C2 - 27777139
AN - SCOPUS:85006459142
SN - 1083-8791
VL - 23
SP - 75
EP - 80
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1
ER -